All
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
We Have Come a Long Way
CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.
Gleevec Response in GIST May Be Linked to Mutational Profile
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.
ctDNA May Predict Biliary Tract Cancer Relapse, Recurrence
Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.
FDA Approves Biosimilars for Cancer-Related Skeletal Events
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.
177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset
177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
The Dawn of a New Era in Cancer Treatment
New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.
Challenging Cancer Stereotypes While Living with Follicular Lymphoma
Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.
BRCA1/2 Mutations May Associate With Better Chemo Response in TNBC
Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.
Calquence Combo May Improve Outcomes in Chronic Lymphocytic Leukemia
Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.
Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.
How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment
The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.
What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.
What’s On the Horizon for Small Cell Lung Cancer Research?
On the heels of two FDA approvals in lung cancer treatments, what innovations are next?
Looking For The Light After MDS
As a cancer survivor, I talk about where to look for the light when in utter darkness.
A Patient’s Journey With Colon Cancer and Her Advocacy Mission
Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.
What Patients Need to Know About Appealing Insurance Denials
The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.
Thermal Ablation Noninferior to Surgery in Small-Size Colorectal Liver Metastases
Treatment with thermal ablation was noninferior to surgical resection in small-size colorectal liver metastases, according to the COLLISION trial.
Organ-Sparing Treatments Bring New Life After Cancer
Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.
Becoming a Better Version of Me After Breast Cancer
A revelation has given me perspective for the New Year, inspiring me to embrace change, set new goals and upgrade myself to a better version in 2025.
Colostomies and Colon Cancer, a Lifesaving Choice, Not a Last Resort
Dr. Andreas M. Kaiser explains how a colostomy may preserve a patient’s health and help to avoid colorectal cancer complications.
Brukinsa Combo Shows Efficacy and Safety For Double-Expressor Lymphoma
Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.
Biomarkers, Genetic Testing and More Make Way in GU Cancers
Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies across kidney, bladder and prostate cancers.
Verzenio Combo May Improve Survival in HR+/HER2– Advanced Breast Cancer
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.
Better Understanding Genetic Mutations Influence in Cancer Care
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Breast Cancer And Depending On The Kindness Of Strangers
I reflect on my unexpected bond with a neighbor during my breast cancer treatment, finding comfort in his company when I needed someone to talk to.
Enhertu Associated With Survival Increase in HER2+ Metastatic Gastric Cancer
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim analysis and potential regulatory approvals.
